ENSYSCE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
ENSYSCE BIOSCIENCES, INC. (ENSC) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $3.12 per share as of 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2025-05-13
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $3.12.
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $3.35.
- 2021-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $3.35.
- 2021-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $3.34.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2025-03-31 | $3.12 10-Q · filed 2025-05-13 |
| 2021-12-31 | $3.35 10-K · filed 2022-03-31 |
| 2021-09-30 | $3.35 10-Q · filed 2021-11-15 |
| 2021-06-30 | $3.34 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |